1
|
Ye H, Yu W, Ni Y, Bao X, Zhang X, Li Y, Chen A, Li J, Zheng L. Apatinib plus chemotherapy is associated with an improved tumor response, survival and tolerance compared with chemotherapy alone for advanced lung adenocarcinoma treatment. Oncol Lett 2024; 27:194. [PMID: 38495832 PMCID: PMC10941069 DOI: 10.3892/ol.2024.14327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2023] [Accepted: 11/13/2023] [Indexed: 03/19/2024] Open
Abstract
Apatinib plus chemotherapy demonstrates good efficacy in multiple advanced carcinomas; however, its use in patients with advanced lung adenocarcinoma (LUAD) has not yet been assessed. The present study evaluated the potential benefits of apatinib plus chemotherapy in patients with advanced LUAD. A total of 145 patients with advanced LUAD and negative driver genes who received apatinib plus chemotherapy (n=65) or chemotherapy alone (n=80) were analyzed. The overall response rate was significantly improved by apatinib plus chemotherapy vs. chemotherapy alone (53.8 vs. 36.3%; P=0.034). Moreover, progression-free survival (PFS) was significantly longer in patients who received apatinib plus chemotherapy, compared with those who received chemotherapy alone [median (95% CI), 13.4 months (11.5-15.3) vs. 8.2 months (6.9-9.5); P<0.001], as was overall survival (OS) [median (95% CI), 23.1 months (not reached) vs. 17.0 months (14.6-19.4; P=0.001). Following adjustment by multivariate Cox regression analysis, apatinib plus chemotherapy was associated with a significantly longer PFS [hazard ratio (HR), 0.444; P<0.001] and OS (HR, 0.347; P<0.001), compared with chemotherapy alone. Subgroup analyses revealed that PFS and OS were significantly improved following apatinib plus chemotherapy vs. chemotherapy alone (all P<0.05) in patients receiving first- or second-line treatment. Notably, the incidence of hypertension was significantly increased following apatinib plus chemotherapy vs. chemotherapy alone (43.1 vs. 25.0%; P=0.021), whereas the incidence of other adverse events was not significantly different between the two treatment groups (all P>0.05). In conclusion, apatinib plus chemotherapy is associated with an improved treatment response and survival compared with chemotherapy alone, with a tolerable safety profile in patients with advanced LUAD.
Collapse
Affiliation(s)
- Hua Ye
- Department of Pulmonary and Critical Care Medicine, Yueqing People's Hospital, Yueqing, Zhejiang 325600, P.R. China
| | - Wenwen Yu
- Department of Pulmonary and Critical Care Medicine, Yueqing People's Hospital, Yueqing, Zhejiang 325600, P.R. China
| | - Yangyang Ni
- Department of Pulmonary and Critical Care Medicine, Yueqing People's Hospital, Yueqing, Zhejiang 325600, P.R. China
| | - Xiaoqiong Bao
- Department of Pulmonary and Critical Care Medicine, Yueqing People's Hospital, Yueqing, Zhejiang 325600, P.R. China
| | - Xie Zhang
- Department of Pulmonary and Critical Care Medicine, Yueqing People's Hospital, Yueqing, Zhejiang 325600, P.R. China
| | - Yunlei Li
- Department of Pulmonary and Critical Care Medicine, Yueqing People's Hospital, Yueqing, Zhejiang 325600, P.R. China
| | - Ali Chen
- Department of Pulmonary and Critical Care Medicine, Yueqing People's Hospital, Yueqing, Zhejiang 325600, P.R. China
| | - Jifa Li
- Department of Pulmonary and Critical Care Medicine, Yueqing People's Hospital, Yueqing, Zhejiang 325600, P.R. China
| | - Long Zheng
- Department of Pulmonary and Critical Care Medicine, Yueqing People's Hospital, Yueqing, Zhejiang 325600, P.R. China
| |
Collapse
|